Punit Dhillon

Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid system ("ECS"). Skye raised $17 million in new capital and acquired Bird Rock Bio...

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that the human research ethics committee in Australia has approved the initiation of the multiple ascending dose ("MAD") arm of Skye's...

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion. As previously announced, this study has received all regulatory...

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) for Skye’s...

Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (“CMO”) for its Phase 2 clinical trial material. “As is typical with...

Skye Bioscience, Inc. (OTCQB: SKYE) has entered into an agreement with Novotech Health Holdings, a leading full-service contract research organization in Asia-Pacific, for its upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma. The San Diego, California-...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The beginning of 2021 marked the start of a busy time for cannabinoid biopharmaceutical company Skye Bioscience, Inc. (OTC: SKYE), not the...

Cannabinoid receptors distributed within the body are part of the endocannabinoid system that largely affects processes such as mood, memory, pain-sensation, and appetite, to name a few. Two types of receptors — CB1 and CB2 — “play a vital role in managing different body...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids....